PharmaShots | Incisive News in 3 Shots

Subscribe Now

chl

BeiGene's Tislelizumab Receives NMPA's Approval for the Treatment of 2L Classical Hodgkin's Lymphoma (cHL)

BeiGene's Tislelizumab Receives NMPA's Approval for the Treatment of 2L Classical Hodgkin's Lymphoma (cHL)

December 31, 2019

Innovent Biologics and Eli Lilly's Tyvyt (Sintilimab injection) Receives NMPA (CFDA) Approval for Classical Hodgkin's Lymphoma (cHL) Patients

Innovent Biologics and Eli Lilly's Tyvyt (Sintilimab injection) Receives NMPA (CFDA) Approval for Classical Hodgkin's Lymphoma (cH...

December 28, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us